GIP infusions resulting in plasma concentrations similar to those observed following oral glucose ingestion, stimulate insulin secretion in a glucose-dependent manner with maximal efficacy at higher postprandial glucose levels, however, its effect is blunted in obesity and T2DM [20, 22]. The gene discussed is INS; the disease is type 2 diabetes mellitus.